Paraneoplastic neurological syndromes with onconeural antibodies: A single center retrospective study

J Neurol Sci. 2020 Nov 15:418:117103. doi: 10.1016/j.jns.2020.117103. Epub 2020 Aug 21.

Abstract

Introduction: Paraneoplastic neurological syndromes (PNS) are immune-mediated diseases that occur in patients with tumors and can be associated with onconeural antibodies. Our aim was to describe our cohort of patients with PNS.

Methods: Retrospective analysis of a cohort of patients followed in a Portuguese tertiary center, with autoantibodies against intracellular antigens from our PNS panel, between 2012 and 2017.

Results: Among the 882 patients with suspected PNS (1029 samples), 37 (4.2%) had positive and 27 (3.1%) weak positive antibodies. A total of 17 (29.3%) PNS were diagnosed, 5 were classic syndromes. Autoantibodies found were anti-Yo, anti-Hu, anti-titin, anti-Ma2, anti-SOX1, anti-Ri and anti-CV2/CRMP5. They were associated with thymoma, breast, colon, parotid gland and lung (small-cell, neuroendocrine or carcinoid) cancer. Among the 17 PNS patients, no tumor was found in 4 (mean follow-up of 46 months); no patients improved with tumor treatment, while 8 improved with immunotherapy; ten patients (59%) died during follow-up. Twenty (60.6%) patients with positive antibodies and 21 (84.0%) with weak positive were not diagnosed with a PNS.

Conclusions: PNS had highly heterogenous clinical presentations. Response to tumor treatment was overall poor, with an unfavorable prognosis. In our cohort, only 29.3% of the patients with positive antibodies were diagnosed with a PNS.

Keywords: Autoimmunity; Onconeural antibodies; Paraneoplastic neurological syndrome.

MeSH terms

  • Autoantibodies
  • Humans
  • Immunotherapy
  • Paraneoplastic Syndromes*
  • Paraneoplastic Syndromes, Nervous System* / diagnosis
  • Paraneoplastic Syndromes, Nervous System* / therapy
  • Retrospective Studies
  • Thymus Neoplasms*

Substances

  • Autoantibodies